
PozeSCAF leverages AxDrug, an AI-driven platform, together with an in-house chemistry facility to accelerate drug discovery from hit identification to lead optimization. It uses a generative AI engine and computational chemistry tools to design and synthesize candidate molecules, integrating AI with synthetic chemistry workflows. Key technologies include AI, Generative AI, Computational Chemistry, Machine Learning, and Deep Learning, with in-house synthesis enabling rapid delivery of compounds. The company provides end-to-end discovery services for pharmaceutical and biotech clients, offering target validation, hit-to-lead generation, lead optimization, and small-molecule synthesis. Its global yet local approach combines remote computational work with an on-site lab to scale R&D programs for customers worldwide.

PozeSCAF leverages AxDrug, an AI-driven platform, together with an in-house chemistry facility to accelerate drug discovery from hit identification to lead optimization. It uses a generative AI engine and computational chemistry tools to design and synthesize candidate molecules, integrating AI with synthetic chemistry workflows. Key technologies include AI, Generative AI, Computational Chemistry, Machine Learning, and Deep Learning, with in-house synthesis enabling rapid delivery of compounds. The company provides end-to-end discovery services for pharmaceutical and biotech clients, offering target validation, hit-to-lead generation, lead optimization, and small-molecule synthesis. Its global yet local approach combines remote computational work with an on-site lab to scale R&D programs for customers worldwide.
What they do: AI-driven drug discovery CRO combining a generative AI platform (AxDrug) with in-house synthesis to deliver hit-to-lead and lead-optimization services
Founded: 2019
Headcount (reported): 32
Industry: Biotechnology
Funding signal: Seed round reported Jan 2025
Small-molecule drug discovery and preclinical lead generation/optimization for pharmaceutical and biotech clients.
2019
Biotechnology
Seed round reported closed Jan 3, 2025